Singapore markets closed

Adial Pharmaceuticals, Inc. (ADIL)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.7000-0.0900 (-5.03%)
At close: 04:00PM EDT
1.7000 0.00 (0.00%)
After hours: 07:30PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.7900
Open1.8000
Bid1.6700 x 100
Ask1.7400 x 500
Day's range1.6700 - 1.8256
52-week range0.7700 - 14.0000
Volume107,241
Avg. volume6,533,883
Market cap6.893M
Beta (5Y monthly)1.53
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Benzinga

    EXCLUSIVE: Alcohol Disorder Focused Adial Pharmaceuticals Secures US Patent

    On April 16, 2024, the United States Patent and Trademark Office issued patent number 11957664 to Adial Pharmaceuticals Inc (NASDAQ:ADIL). This patent expands Adial’s intellectual property protection and covers the combination of the company’s proprietary genetic diagnostic to identify patients with specific genotypes for genetically targeted treatment of alcohol use disorder (AUD) and other drug dependencies, such as opioid use disorder (OUD), with the company’s lead investigational new drug pr

  • Zacks

    Is Masimo (MASI) Outperforming Other Medical Stocks This Year?

    Here is how Masimo (MASI) and Adial Pharmaceuticals, Inc. (ADIL) have performed compared to their sector so far this year.

  • Benzinga

    EXCLUSIVE: Adial Pharmaceuticals Secures New US Patent Covering Lead Product For Alcohol Use Disorder

    Wednesday, Adial Pharmaceuticals Inc (NASDAQ:ADIL) announced patent number 11,905,562 was issued on February 20, 2024, by the United States Patent and Trademark Office. The patent covers the company’s lead investigational new drug product, AD04, and its ability to target the serotonin transporter gene for the potential treatment of opioid use disorder. The company says the new patent strengthens Adial’s patent portfolio and covers AD04’s ability to target the serotonin transporter gene for the p